Geode Capital Management LLC Sells 3,966 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

Geode Capital Management LLC decreased its position in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 0.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,973,116 shares of the company’s stock after selling 3,966 shares during the quarter. Geode Capital Management LLC owned about 2.31% of Syndax Pharmaceuticals worth $26,091,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of SNDX. Assenagon Asset Management S.A. increased its stake in Syndax Pharmaceuticals by 343.0% during the 4th quarter. Assenagon Asset Management S.A. now owns 2,064,456 shares of the company’s stock valued at $27,292,000 after purchasing an additional 1,598,428 shares in the last quarter. Franklin Resources Inc. raised its holdings in shares of Syndax Pharmaceuticals by 13.4% in the 3rd quarter. Franklin Resources Inc. now owns 1,763,277 shares of the company’s stock worth $34,948,000 after acquiring an additional 208,043 shares during the last quarter. Barclays PLC raised its holdings in shares of Syndax Pharmaceuticals by 143.4% in the 3rd quarter. Barclays PLC now owns 187,629 shares of the company’s stock worth $3,612,000 after acquiring an additional 110,535 shares during the last quarter. abrdn plc bought a new position in Syndax Pharmaceuticals in the 4th quarter valued at about $1,313,000. Finally, State of New Jersey Common Pension Fund D boosted its stake in Syndax Pharmaceuticals by 40.5% during the 4th quarter. State of New Jersey Common Pension Fund D now owns 133,111 shares of the company’s stock valued at $1,760,000 after purchasing an additional 38,339 shares during the last quarter.

Wall Street Analyst Weigh In

Several analysts have recently commented on SNDX shares. Citigroup lowered their price objective on Syndax Pharmaceuticals from $45.00 to $42.00 and set a “buy” rating for the company in a research note on Tuesday, March 4th. Scotiabank lowered their price target on Syndax Pharmaceuticals from $18.00 to $16.00 and set a “sector perform” rating for the company in a research report on Wednesday, January 8th. JPMorgan Chase & Co. lifted their price objective on shares of Syndax Pharmaceuticals from $39.00 to $41.00 and gave the stock an “overweight” rating in a report on Thursday, March 20th. HC Wainwright reiterated a “buy” rating and issued a $51.00 target price on shares of Syndax Pharmaceuticals in a report on Tuesday, March 4th. Finally, StockNews.com upgraded shares of Syndax Pharmaceuticals to a “sell” rating in a report on Thursday, April 10th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, Syndax Pharmaceuticals presently has a consensus rating of “Moderate Buy” and a consensus target price of $36.20.

Insider Buying and Selling at Syndax Pharmaceuticals

In related news, CFO Keith A. Goldan sold 3,777 shares of Syndax Pharmaceuticals stock in a transaction dated Monday, February 10th. The stock was sold at an average price of $15.50, for a total value of $58,543.50. Following the completion of the sale, the chief financial officer now owns 90,746 shares of the company’s stock, valued at approximately $1,406,563. This trade represents a 4.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CEO Michael A. Metzger sold 13,288 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were sold at an average price of $15.50, for a total transaction of $205,964.00. Following the sale, the chief executive officer now directly owns 300,121 shares in the company, valued at approximately $4,651,875.50. This trade represents a 4.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 21,683 shares of company stock worth $336,087 over the last ninety days. 4.10% of the stock is currently owned by company insiders.

Syndax Pharmaceuticals Stock Performance

Shares of SNDX stock opened at $11.51 on Friday. Syndax Pharmaceuticals, Inc. has a 52 week low of $9.66 and a 52 week high of $25.07. The firm’s 50-day simple moving average is $13.34 and its two-hundred day simple moving average is $15.15. The firm has a market cap of $989.94 million, a price-to-earnings ratio of -3.17 and a beta of 1.28.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($1.10) EPS for the quarter, missing analysts’ consensus estimates of ($0.31) by ($0.79). The company had revenue of $7.68 million for the quarter, compared to the consensus estimate of $86.32 million. Analysts forecast that Syndax Pharmaceuticals, Inc. will post -3.72 earnings per share for the current year.

Syndax Pharmaceuticals Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).